Researchers writing in Arthritis Research & Therapy have outlined some factors that influence DNA methylation, also known as epigentics. In this slideshow, we highlight the factors.
What is nature's role in the development of inflammatory bowel disease, psoriasis and ankylosing spondylitis?
In an effort to determine what causes immune mediated diseases such as ankylosing spondylitis, inflammatory bowel disease and psoriasis, researchers have focused on learning more about genetic pathogenic pathways responsible for autoimmunity. In this article, we review the data and highlight best practices.
Reactive arthritis is an inflammatory joint arthritis largely characterized by joint inflammation triggered by infection. To date, no diagnostic or classification criteria have been established, but in 2014, the American College of Rheumatology issued general treatment guidelines. In this article, we highlight a new review article on treatments for reactive arthritis.
A 40-year-old man presents to his primary care doctor complaining of pain in his ankles, knees, feet, heels, lower back and buttocks. What's your diagnosis?
In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.
From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics.
Glucocorticoids are highly effective in treating inflammatory conditions. However, these medications also pose a significant risk for bone loss and fracture. In this slideshow, we cover the treatment guidelines.
Remission is unlikely in non-radiographic axial spondyloarthritis without biologic therapy. Adding certolizumab to background therapy can lead to significant improvements in disease activity compared to placebo, researchers find.
In a recent edition of Frontiers in Immunology, Dr. Walter Maksymowych, University of Alberta, reviews the use of biomarkers for diagnosis and prognosis in axial spondyloarthritis. Learn more in this summary.
In rheumatology, there have been five new drug approvals in recent months for patients with rheumatoid arthritis, axial spondyloarthritis, plaque psoriasis, osteoporosis, among other conditions. Learn more about the new treatments and other drug news in this slideshow.